MDGL
Madrigal Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
507.37
close · 2026-08-13
value
18
cheaper than peers18
quality
49
stronger fundamentals49
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 10.04× | 57 |
| forward P/E | 52.71× | 14 |
| price to book | 22.37× | 13 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 126.8% | 79 |
| operating margin | -29.8% | 60 |
| return on equity | -49.3% | 36 |
| debt to equity | 63.9% | 29 |
4 of 4 measures available
Facts
| market cap | $12B |
| free cash flow | -$156.4M |
| employees | 915 |
| first trade | 2007-02-06 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-07-30 |